|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Sponsor** | **Description** | **Platform** | **Funders** | **Status** | **Considerations** | **Storage Temp** |
| Moderna | **mRNA-1273** Synthetic messenger RNA that encodes for SARSCoV-2 spike protein. | mRNA | USG1 ($2.48B)CEPI2/GAVI3 (Undisclosed)Warp Speed FinalistCOVAX Portfolio4 | Ph. I ongoing:• 155 vols/US• Preliminary dataPh. II ongoing: • 600 vols/USPh. III ongoing: • 30,000 vols/US | **Immunogenicity:** Ph. I data showed after two doses volunteers had more neutralizing antibodies than most individuals who have recovered from COVID.**Manufacturing/delivery:** mRNA vaccines are relatively easy to scale and manufacture (potential for 1B doses by 2022); likely to require two doses, but athird may be necessary.**Platform history:** No licensed mRNA vaccines. | -80⁰C |
| AstraZeneca | **AZD1222**Chimpanzee Adeno vectorexpressing SARS-CoV-2spike protein. | Viral vector | USG ($1.2B)CEPI/GAVI ($750M)EU ($923M)Warp Speed FinalistCOVAX Portfolio | Ph. I/II ongoing: • 1090 vols/UKPh. II/II ongoing:• 12,330 vols/UK;• 5000/Brazil, South Africa• 1700/IndiaPh. III ongoing: • 30K vols/US | **Immunogenicity:** Preliminary Ph. I/II data showed both antibody and T-cell responses.**Manufacturing/delivery:** Adeno vector vaccines could conceivably bemanufactured quickly and at scale (capacity to produce 2B doses has already been secured).**Platform history:** No Adeno vector vaccines currently licensed for use in humans. | 2-8⁰C |
| Janssen | **JNJ-78436735** Ad26 vector expressing SARS-CoV-2 spike protein. | Viral vector | USG ($1.45B)J&J investment (~$500M)Warp Speed Finalist | Ph. I/IIa ongoing: • 1045 vols/US and BelgiumPh. III ongoing: • 60K vols/ US, Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa. | **Immunogenicity:** Preclinical data shows that protected monkeys after one dose; the potential for preexisting immunity against Ad26.**Manufacturing/delivery:** Product does not need to be stored at subzerotemperatures, and it may require just a single dose.**Platform history:** Utilizes the same technology used to make its Ebola vaccine,which was granted European regulatory approval in May 2020. | 2-8⁰C |
| Novavax | **NVX-COV2373**Full-length recombinantSARS-CoV-2 spike proteinnanoparticle vaccineadjuvanted with Matrix-M. | Protein Subunit | USG ($1.6B)CEPI ($388M)Warp Speed FinalistCOVAX Portfolio | Ph. I ongoing: • 131/1,288 vols/ Australia + USPh. II ongoing: • 4,422 vols/ South AfricaPh. III ongoing:• 15,203 vols/ UK(Sep. 2020)Ph. III planned: • 30,000 vols/US+(Dec. 2020) | **Immunogenicity:** Ph. I data showed both antibody and T-cell responses.**Manufacturing/delivery:** GMP production initiated with capacity for large-scalemanufacturing (est. 1B doses by end of 2021).**Platform history:** The same nanoparticle platform succeeded in a Ph. III trial forNanoFlu, an influenza vaccine for older adults. | 2-8⁰C |
| Sanofi | A truncated version of the SARS-CoV-2 spike protein is produced by insect cells, then purified and combined with GSK’s pandemic AS03 adjuvant. | Protein | USG ($2.1B)Warp Speed Finalist | Ph. I/II planned: • Sept. 2020Ph. III planned: • 30K vols/US+ (Dec. 2020) | **Immunogenicity:** TBC**Manufacturing/delivery:** The adjuvant system is designed to boost the immuneresponse and allow less to be used per dose, potentially allowing more doses to besupplied. GSK will manufacture 1B doses of its adjuvant system in 2021.**Platform history:** Same platform as vaccine candidates for Influenza (FDA approved vaccine), SARS-CoV. | 2-8⁰C |

1. USG: United States Government
2. CEPI: Coalition for Epidemic Preparedness Innovations
3. Gavi, the Vaccine Alliance
4. COVAX: The vaccine pillar of ACT-A, the global collaboration to accelerate development, production and equitable access to new diagnostics, therapeutics and vaccines. COVAX is led by GAVI, CEPI and the World Health Organization (WHO).